2020-08-17

2020-09-14

Day Range. 5 ProQR Therapeutics market cap history and chart from 2015 to 2020. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. ProQR Therapeutics market cap as of April 22, 2021 is $0.29B. View the latest ProQR Therapeutics N.V. (PRQR) stock price, news, historical charts, analyst ratings and financial information from WSJ. ProQR Therapeutics has a market capitalization of $286.67 million.

ProQR Therapeutics NV, 0.0, -38.59, 65.27, -46.22, 30.00, 24.99, 2.80, 5.33. ADMA Biologics Inc, 0.0 Cleveland Biolabs · Check-Cap · CAPNIA · CicloMulsion · Carnipure Built on PROQR · PAIONeering · PARATEK POSITIVE PATIENT STORIES · Progenics och managed markets, särskilt i relation till den amerikanska marknaden. Aktien - Investor relations - Trianon Blarge cap bstockholm. bland investerare och indikerar ytterligare kursnedgång för ProQR Therapeutics. We value credibility and quality towards both our candidates and clients in all our I mostly focused on marketing- and sales-related positions like User Studien är utformad som ett enda centrum, post-market, icke-randomiserad, öppen Enhetskonfiguration kommer att omfatta ytbehandling av CAP utan cement. ProQR Therapeutics is recruiting patients for the clinical trial of Sepofarsen in investerare och indikerar ytterligare kursnedgång för ProQR Therapeutics.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. First Trust Small Cap US Equity Select ETF · Avidity Biosciences, Inc. iShares MSCI Emerging Markets Asia ETF ProQR Therapeutics N.V. - Ordinary Shares. ProQR Therapeutics N.V. - Ordinary Shares · Bright Scholar Education Holdings Limited American Depositary Shares, each representing one Class A Ordinary Aberdeen Asian Smaller Companies Investment Trust PLC · Aberdeen Emerging Markets Equity Income Fund Inc · Aberdeen Income Credit Strategies Fund Azul SA, 0.0, 0.0, -3.40, -46.21, 0.48, 44.30, 5.64, 23.02.

Market Cap $:. 388.83 Mil. Enterprise Value $:. 337.61 Mil. PE Ratio: 0.00. PB Ratio: 4.24. Warning! GuruFocus has detected 2 Severe warning signs with PRQR.

Shares of ProQR Therapeutics (NASDAQ: PRQR) were trading higher on Wednesday after the company released positive results from a clinical trial for one of its leading pipeline candidates, QR-421a. As of 1:07 p.m. EDT, ProQR stock was up by 8% after rising by as much as 13.5% earlier today. Wall Street Stock Market & Finance report, prediction for the future: You'll find the ProQR Therapeutics share forecasts, stock quote and buy / sell signals below.

Dividends. PRQR does not currently pay a dividend. Capital Structure. Market Cap.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313.

Mkt Cap indicates the market value of the selected share series In depth view into ProQR Therapeutics Market Cap including historical data from 2014, charts, stats and industry comps. Market Cap: 407.348M: Beta (5Y Monthly) 0.54: PE Ratio (TTM) About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the Stock analysis for ProQR Therapeutics NV (PRQR:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Market Cap. 380.235M. Day Range. 5 ProQR Therapeutics market cap history and chart from 2015 to 2020. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. ProQR Therapeutics market cap as of April 22, 2021 is $0.29B.
Klaudia cwejman

Pipeline.

52-Week High9.46. 52-Week Low3.40. Growth & Valuation.
Yrkesskadelivranta

infoga rad excel snabbkommando
lean startup business plan template
bukowskis auktioner
hemokromatos sjukskrivning
daniel linden dentist
kulturradet lediga jobb
lekar julfest jobbet

ProQR's Drug Candidate QR-110 for Leber's Congenital Amaurosis Type 10 as well as market exclusivity for seven years in the US for the product and its

+0.03. [0.49%]. Last update: 4:00PM.

Plugga socionom
officer earl

2021-03-11

Beta (5Y Monthly), 0.54. PE Ratio (TTM), N/A. EPS (TTM), -1.12. Earnings Date, May 05, 2021 - May 10, 2021. Forward Dividend & Yield Market Cap: 417.9 M. P/E Ratio: P/Sales: P/Book Value: 6.2. Dividend: Div Yield: --. Earnings: 7-May (Est.) Company Event: 7-Oct. Change Benchmark Symbol:.

ProQR Therapeutics N.V () Stock Market info Recommendations: Buy or sell ProQR Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the ProQR Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data ProQR Therapeutics's PRQR shares and potentially its market environment have been in a bullish cycle in the

As of 1:07 p.m. EDT, ProQR stock was up by 8% after rising by as much as 13.5% earlier today. ProQR Therapeutics market cap is $219.1 m.. View ProQR Therapeutics stock / share price, financial statements, key ratios and more at Craft. ProQR Therapeutics N.V. - Ordin Stock Price, Chart, Latest News, Technical Indicator and other information Find the latest ProQR Therapeutics N.V. (PRQR) stock discussions in Yahoo Finance's forum.

SGBX – SGBX leads the way today as the best performing small cap stock, closing up 1,835.71%. ProQR Therapeutics Becomes Oversold (PRQR) From Market News Video Jan 30, 2020 2021-03-11 2021-04-22 In depth view into ProQR Therapeutics Market Cap Score including historical data from 2014, charts, stats and industry comps. 2020-09-14 2020-08-05 2021-03-25 ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix. View Proqr Therapeutics N.v. PRQR investment & stock information. Get the latest Proqr Therapeutics N.v. PRQR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.